RxDoctor Payments Data

Barbara Hagey, DPM

Podiatrist · Parkersburg, WVNPI 1275570343

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.8% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Smith+Nephew at 42.0% of the total. Reporting peaked in 2021 at $269 and has fallen 83.9% since, to $43 in 2025. That places this record below the midpoint for podiatrist clinicians in WV, where the typical reported total is $1,242.

$862in general payments, 2019–2025

Across 37 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$362
  • Stryker$206
  • Organogenesis Inc.$172
  • AbbVie$42
  • Bioventus LLC$25
  • Trice Medical, Inc.$23
  • plus $32 from 2 others

What the payments were for

  • Speaking & faculty fees$809%
  • Food & beverage$78291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$862 in reported general payments places this provider in the 35th percentile of 37 podiatrist providers in West Virginia.

See all podiatrist providers in West Virginia

Medicare billing

Part B allowed, 2024
$46,936
Medicare patients
270
Services billed
1,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cephalexin23$220
Meloxicam11$16

Paid to pharmacies, not to this prescriber.

Other podiatrist in Parkersburg

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →